Central Retinal Vein Occlusion — Cost, Top Hospitals & Success Rates | MyMedicPlus

Central retinal vein occlusion (CRVO) is a major retinal vascular disorder characterised by acute thrombotic obstruction of the central retinal vein at or posterior to the lamina cribrosa, the sieve-like structure through which the retinal vessels enter and exit the eye at the optic disc. This obstruction causes a dramatic rise in venous pressure throughout the retinal venous system, leading to widespread retinal haemorrhages in all four quadrants, macular oedema (swelling of the central retina), disc oedema, dilated tortuous retinal veins, and — in severe ischaemic cases — retinal non-perfusion and secondary neovascular glaucoma.

CRVO presents as a sudden, painless reduction in vision — typically unilateral — ranging from mild blurring to profound visual loss, depending on whether the macula (central vision area) is involved and whether the occlusion is non-ischaemic (perfused, better prognosis) or ischaemic (large areas of retinal non-perfusion, high risk of neovascular complications and severe visual loss). The distinction is made by fundus fluorescein angiography.

The primary treatment target in contemporary practice is macular oedema — the principal cause of chronic visual impairment after CRVO — addressed by intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents (ranibizumab, bevacizumab, aflibercept, faricimab) which reduce vascular permeability and macular swelling. Intravitreal corticosteroid implants (dexamethasone implant — Ozurdex) are an alternative, particularly for patients who are pseudophakic (with an implanted lens) and tolerant of the cataract-forming side effect. Risk factor management — treating hypertension, diabetes, hyperlipidaemia, and thrombophilia — is essential to prevent fellow eye involvement and systemic vascular events.

Central retinal vein occlusion is the diagnosis primarily treated by the management strategies described. CRVO is classified by degree of retinal ischaemia: non-ischaemic CRVO (the majority, approximately 75%) has intact capillary perfusion on fluorescein angiography and carries a better visual prognosis; ischaemic CRVO (approximately 25%) shows extensive capillary non-perfusion and carries high risk of neovascular complications — neovascular glaucoma (NVG) from anterior segment neovascularisation, and vitreous haemorrhage from retinal new vessels — potentially causing irreversible vision loss. Macular oedema secondary to CRVO — the principal treatable cause of visual impairment — responds to anti-VEGF injections in approximately 50–70% of patients.

Branch retinal vein occlusion (BRVO) — occlusion of one of the four major branch veins — is a closely related condition treated with the same anti-VEGF and corticosteroid approaches for macular oedema. BRVO affects a quadrant of the retina rather than the entire retina, and carries a better overall visual prognosis than CRVO. Both CRVO and BRVO are associated with systemic cardiovascular risk factors and require systemic evaluation and risk factor modification by the patient's primary physician or cardiologist in parallel with ophthalmic treatment.

All patients with visual loss from macular oedema secondary to CRVO — confirmed by optical coherence tomography (OCT) showing central subfield thickness above 300–350 microns — are candidates for intravitreal anti-VEGF treatment, provided they can tolerate repeated bilateral clinic visits and intravitreal injections. The CRUISE and GALILEO trials established the efficacy of ranibizumab and aflibercept respectively for CRVO macular oedema. There is no age limit for treatment; patients from their 30s to their 90s are treated. Treatment is initiated promptly after diagnosis, as earlier treatment correlates with better visual outcomes.

Intravitreal dexamethasone implant (Ozurdex) is an alternative for patients who cannot commit to monthly anti-VEGF injections (though its injection interval is every three to four months), and is particularly appropriate for pseudophakic patients in whom cataract formation from the steroid is not a concern. For patients with ischaemic CRVO and neovascular glaucoma, anti-VEGF injections combined with pan-retinal photocoagulation (PRP) and aggressive IOP management (topical drops, glaucoma surgery if needed) are required urgently. Patients with concurrent systemic conditions (coagulopathy, vasculitis, thrombophilia) require haematological or rheumatological assessment alongside ophthalmic treatment.

Intravitreal anti-VEGF injection is the first-line treatment for macular oedema from CRVO. Ranibizumab (Lucentis, Byooviz) 0.5 mg, bevacizumab (Avastin — off-label) 1.25 mg, aflibercept (Eylea, Eylea HD) 2 mg, and faricimab (Vabysmo) 6 mg are the available agents. They are injected through the pars plana (white of the eye) under topical anaesthesia as a two-minute outpatient procedure. A standard loading phase of three monthly injections is typically followed by a treat-and-extend or pro re nata protocol guided by OCT macular thickness. Monthly monitoring with OCT is the standard of care in the first year.

Intravitreal dexamethasone implant (Ozurdex) — a 0.7 mg sustained-release biodegradable steroid implant — reduces CRVO macular oedema for approximately three to four months per injection, requiring fewer injections than anti-VEGF therapy. However, it consistently causes IOP elevation (requiring topical drops in 25–30% of patients), accelerates posterior subcapsular cataract in phakic patients, and is therefore preferred in pseudophakic patients and those with a history of poor anti-VEGF response. Pan-retinal photocoagulation (PRP) laser — treating the ischaemic peripheral retina to reduce VEGF production — is indicated in ischaemic CRVO to prevent or treat neovascular complications. It does not improve central vision but reduces the risk of NVG and vitreous haemorrhage.

Anti-VEGF treatment for CRVO macular oedema provides meaningful visual improvement in the majority of patients. In the CRUISE trial (ranibizumab), 47% of treated patients gained 15 or more ETDRS letters (3 Snellen lines) of vision at six months compared to 17% with sham. In the GALILEO trial (aflibercept), 60% of treated patients gained 15 or more letters at one year compared to 32% with sham. Visual gains are most pronounced in patients with better baseline visual acuity, shorter duration before treatment initiation, and non-ischaemic disease.

However, visual outcomes in CRVO are more modest and less durable than in wet age-related macular degeneration, reflecting the structural damage from widespread retinal haemorrhage, disc oedema, and ischaemia in CRVO that limits the ceiling of recoverable visual acuity. Approximately 30–40% of CRVO eyes achieve 6/12 or better vision with treatment, while 15–25% remain severely visually impaired despite optimum therapy — often due to macular ischaemia that cannot be reversed by anti-VEGF treatment. Regular maintenance injections are required in the majority of patients for one to two or more years, as discontinuation of anti-VEGF commonly leads to macular oedema recurrence.

Intravitreal injection is a safe procedure when performed with standard aseptic technique in a clean clinical environment. Endophthalmitis — intraocular infection — is the most feared complication, occurring in approximately 1 in 1,000–2,000 injections and presenting with rapid progressive pain and visual loss. Immediate intravitreal antibiotic injection is required. Sustained use of povidone-iodine antisepsis before injection and use of a speculum without lid contact reduces endophthalmitis risk substantially. Injection-related complications include retinal tear, retinal detachment, vitreous haemorrhage, and elevated IOP from the bolus injection — each occurring in below 0.5% per injection.

Cardiovascular events — non-fatal MI, stroke, vascular death — are a theoretical concern with systemic anti-VEGF absorption after intravitreal injection; however, the ocular doses used are pharmacologically minor and large meta-analyses have not demonstrated significantly increased cardiovascular event rates with ranibizumab, bevacizumab, or aflibercept intravitreal injections. Dexamethasone implant consistently causes IOP elevation above 25 mmHg in approximately 25–30% of patients, requiring topical IOP-lowering drops, and should not be used in patients with pre-existing glaucoma. Posterior subcapsular cataract formation from dexamethasone occurs in the majority of phakic patients receiving three or more Ozurdex implants.

CRVO is a chronic condition requiring long-term ophthalmological follow-up. Anti-VEGF therapy typically involves monthly OCT monitoring and injections in the first three to six months, transitioning to a treat-and-extend protocol (extending the interval by two weeks when the macula is dry, shortening it when oedema recurs) to reduce injection burden while maintaining optimal macular anatomy. Most patients require ongoing treatment for one to three or more years; a minority of CRVO eyes achieve durable resolution and can be monitored without further treatment.

Blood pressure, fasting glucose, lipid profile, and full blood count are monitored by the patient's primary physician to address the systemic risk factors for both recurrence in the affected eye and fellow eye involvement. Patients over 50 require cardiovascular risk stratification. Younger patients (below 50) with CRVO should be investigated for thrombophilia (factor V Leiden, prothrombin mutation, antiphospholipid syndrome), hyperhomocysteinaemia, systemic vasculitis, and haematological disorders. Visual field testing and IOP monitoring at every visit screens for ischaemic CRVO-related neovascular glaucoma. Driving restrictions apply if visual acuity in the affected eye (or both eyes combined) falls below the legal driving standard.

Anti-VEGF injections are expensive on a per-injection basis and are required monthly to bimonthly for one or more years in most CRVO patients. In the United States, branded ranibizumab (Lucentis) costs USD 1,900–2,000 per injection; aflibercept (Eylea) USD 1,850–2,000; bevacizumab (Avastin, compounded off-label) USD 50–80. With monthly injections for twelve months, annual bevacizumab cost is approximately USD 600–1,000 per eye; branded agents USD 22,000–24,000. UK NHS provides anti-VEGF treatment for CRVO on NICE guidance (TA283: ranibizumab; TA461: aflibercept).

In India, branded aflibercept costs approximately USD 300–400 per injection; bevacizumab (repackaged) USD 30–50. Full annual treatment at a major Indian eye hospital costs USD 1,500–5,000 including all injections and monitoring OCTs — a saving of 85–95% versus US branded drug costs. Aravind Eye Care System, LV Prasad Eye Institute, Sankara Nethralaya, and Shroff's Charity Eye Hospital are world-class Indian retina centres. Thailand (Bangkok Eye Care Hospital, Rutnin Eye) charges USD 500–1,000 per injection; Turkey USD 400–800. For patients requiring long-term maintenance treatment, the cost savings of accessing anti-VEGF therapy in India or Thailand over several years can be substantial.

Grid macular laser photocoagulation — laser treatment of macular leakage sites — was the historical standard for CRVO macular oedema before anti-VEGF therapy. The SCORE trial demonstrated the superiority of intravitreal triamcinolone over grid laser, and anti-VEGF agents have subsequently replaced both as first-line therapy. Grid laser is now reserved for chronic macular oedema that is partially controlled and in which laser can target discrete leaking microaneurysms. Systemic anticoagulation has not been demonstrated to be beneficial in acute CRVO and is not recommended for routine use. Haemodilution and pentoxifylline to improve retinal microcirculation have been studied but lack strong evidence. Radial optic neurotomy — surgical incision of the scleral ring around the optic disc to decompress the central retinal vein — is a historical experimental surgical approach that has not been adopted in standard practice due to inconsistent outcomes and significant surgical risk.